Jinxin Fertility cashes in on sector novelty for HK$3bn IPO

By Jonathan Breen
19 Jun 2019

China’s Jinxin Fertility Group has raised HK$2.99bn ($381.9m) from its Hong Kong listing after riding a wave of investor demand for healthcare stocks.

The issuer attracted further attention for its particular niche in the healthcare industry — providing assisted reproductive services (ARS) such as in vitro fertilisation (IVF) treatments — which helped it pull off a popular IPO amid tumultuous global markets.

“Last week we had ESR Cayman, which was difficult,” ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial